Alltrna Announces Series B Raise of $109 Million to Advance tRNA Medicines for Stop Codon Disease

Alltrna is advancing a new class of genetic medicines based on the power of tRNA biology to universally treat Stop Codon Disease, which encompasses thousands of genetic diseases caused by a premature termination codon (PTC) mutation and affects approximate... Biopharmaceuticals, Venture Capital Alltrna , Stop Codon Disease, tRNA
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news